Materials and Methods
GmbH, Nussloch, Germany), approximately 40-micron thick sections were prepared at five levels of interest in the sagittal plane representing all major tissues, organs and fluids. The radioactivity in the sections and externally applied 14 C-standards was analyzed by exposing to Molecular Dynamics PhosphorImager screens for four days.
The exposed screens were scanned using Molecular Dynamics 445 SI PhosphorImager (Amersham Biosciences, Piscataway, NJ). Tissue concentrations of radioactivity were interpolated from the standard curve generated from 14 C-standards as µg Eq of [ 14 C]cinacalcet/g of tissue.
Gradient chromatography was performed using YMC-basic column (2.1 mm x 250 mm) and Agilent HP 1100 HPLC module (Agilent Technologies Inc., Palo Alto, CA) connected to flow scintillation analyzer (β-RAM radiometric detector, IN/US Systems, Tampa, FL).
LC-MS/MS analyses for structural determination were performed using an LCQ (ThermoFinnigan, San Jose, CA) or VG Quattro (Micromass Corp., Beverley, MA) mass spectrometers with electrospray source and operated in positive or negative ionization mode. For NMR analysis, metabolites were isolated by fraction collection and were dissolved in deuterated methanol. Proton and carbon-13 resonance spectra were acquired using a Bruker drx-500 NMR spectrometer (Bruker BioSpin Corp., Germany).
The metabolite characterization in this study was based on the assignments made from the extensive studies done with cinacalcet and its dihydrodiol metabolites (M2), generated in vitro in human liver microsomes, by 1D proton, 2D COSY, 2D TOCSY, 2D
NOESY, HMBC and in some cases diffusion-edited spectra (Personal Communication, L. Poppe).
Quantitation of cinacalcet in monkey and human plasma was performed by LC/MS/MS using electrospray ionization with heptadeuterated cinacalcet as an internal standard.
Extraction was performed using Oasis MCX 96-well extraction plates (Waters Corp., Milford, MA) and chromatography was performed using Keystone Inertsil Silica column (2x50mm, 5 µm particle size). The mobile phase was 90:10 acetonitrile:water with 1% formic acid. Non-compartmental analysis was performed using WinNonlin (v3.1, PharSight Corporation, Mountain View, CA).
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Results:
Tissue Distribution: The [ 14 C-2-CH 2 ]cinacalcet-derived radioactivity levels in select tissues in rats are summarized in Table 1 . For all other tissues examined, including the central nervous system, skeletal muscle, testes, abdominal fat and the eye, the tissue to plasma ratios (T/P) were low (<0.5). The total radioactivity levels in blood were lower than plasma (blood/plasma ratio < 0.4), suggesting that there was minimal uptake of cinacalcet-derived radioactivity into the cellular elements of the blood. Radioactivity was widely distributed into the tissues, with no apparent gender-related differences. The decline in radioactivity levels in tissues over the 48 h period examined was approximately parallel to that in plasma. Relatively higher levels of radioactivity compared to plasma were observed in highly-perfused organs such as kidney, liver, lung and pancreas. As expected following oral dosing, highest levels of radioactivity were associated with the contents of gastrointestinal tract, with AUC (48 h) of radioactivity for the contents of stomach, small and large intestines, and cecum ranging from 1140 to 1510 mg Eq•h/g (Table 1 ).
Pharmacokinetics. In monkeys, following 10 mg/kg dosing of [ 14 C-CF 3 ]cinacalcet, the maximum concentrations of radioactivity as well as cinacalcet levels were attained approximately at a similar time (Table 2 , Fig 1) . The absorption of [ 14 C-CF 3 ]cinacalcetderived radioactivity was at least 74% based on the recovery of radioactivity in the urine and bile (Table 3) . There was an approximately dose-proportional increase in AUC of both total plasma radioactivity and cinacalcet between 10 and 100 mg/kg doses. Based on the comparison of AUC of unchanged cinacalcet and total plasma radioactivity, less than 0.5% of the cinacalcet-derived radioactivity in plasma was due to the unchanged parent in monkeys. The apparent shorter terminal half-life of cinacalcet compared to total radioactivity is probably an artifact due to levels of cinacalcet below the limit of quantitation beyond 24 hours post-dose.
After oral administration of [ 14 C-CF 3 ]cinacalcet to humans, maximum concentrations of cinacalcet as well as radioactivity occurred within three hours after administration (Fig 2) .
In humans, the absorption of cinacalcet-derived radioactivity was high (at least approximately 80%), based on total urinary excretion of radioactivity (Table 3 ). The plasma profile of cinacalcet and total radioactivity suggests that metabolites were not longer lived than cinacalcet in humans. The AUC 0-t ratio of total radioactivity in human blood and plasma was approximately 0.44 ( Table 2 ), suggesting that there was no significant uptake of cinacalcet-derived radioactivity into blood cells. However, in an in vitro experiment conducted with human blood, the blood to plasma ratio of cinacalcet was approximately one (Personal communication, Dr. S. Surapaneni), indicating that while cinacalcet itself distributes into blood cells, its metabolites probably do not. Based on the AUC ratio of total plasma radioactivity to unchanged cinacalcet, less than 0.5% of the cinacalcet-derived radioactivity in plasma was due to unchanged parent in humans.
Metabolites of cinacalcet constitute the predominant portion of the cinacalcet-derived circulating radioactivity in both humans and animal models. No marked differences in the pharmacokinetics of cinacalcet were observed between nonsmoking and smoking subjects.
Excretion of Radioactivity:
The excretion of radioactivity in animals and humans is summarized in Table 3 . In mice, radioactivity was rapidly excreted, with the majority being excreted during the first 24 h following dosing. The excretion of radioactivity in urine accounted for 50.6% and 69.0% of the dose in male and female mice, respectively. Table 2 ).
Excretion in the feces accounted for 13-17% of the radioactive dose. The mean recovery of radioactivity in excreta was 96-97% of the dose. There were no marked differences in the excretion of radioactivity between smoking and non-smoking subjects.
Metabolite Identification:
Cinacalcet: The protonated molecular ion of cinacalcet was observed at m/z 358 (MH + ) (Fig 4) . (Fig 5) . The major changes in chemical shifts in M8-Gly were for aromatic proton H-12 (7.46 ppm in cinacalcet compared to 8.21 ppm in M8-Gly) and H-15 (7.39 ppm of cinacalcet compared to 8.15 ppm of M8-Gly) (Fig 5) . These data indicate that a modification has occurred on the carbon between C12 and C-15 of M8-Gly. Additionally, ppm) were also in the expected region, further confirming the presence of glycine moiety in M8-Gly. Based on these data, M8-Gly was identified as the glycine conjugate of mtrifluoromethyl benzoic acid.
M1-Glu:
Metabolite M1-Glu (m/z 550) was observed as two peaks in urine and bile of monkeys. There were two distinct patterns of fragmentation of M1-Glu (Fig 7) . The 
M3-Glu:
The protonated molecular ion of minor metabolites M3-Glu, present in monkey bile and urine, was observed at m/z 584 (M+H) + (Fig 7) . M3-Glu, present as two peaks, yielded two distinct fragment patterns. The corresponding aglycones, M3, were observed in mouse feces. The major diagnostic fragments from these two metabolites were m/z 204 (corresponding to m-CF 3 -phenyl-CH 2 -CH 2 -CH 2 -NH) or m/z 220 (corresponding to oxidized m-CF 3 -phenyl-CH 2 -CH 2 -CH 2 -NH). These data indicated that metabolites M3-Glu are further oxidation products of M2-Glu, with oxidation occurring on Composition of excreta and plasma radioactivity:
Metabolites of cinacalcet were the predominant components of excreta radioactivity in mice (Fig 8 and Table 4 ). The major metabolite in urine was M7-Gly (glycine conjugate of 3'-trifluoromethyl cinnamic acid). In feces, the major metabolite was M2a (dihydrodiol of cinacalcet). It is likely that the M2-Glu, excreted via bile, was hydrolysed to its aglycone in gastrointestinal tract. In mouse feces, M4, a metabolite corresponding to an authentic standard of m-CF 3 -phenyl-CH 2 -CH 2 -CH 2 -NH 2 (m/z 204) was observed. The major components of plasma radioactivity in mice were M5 and M7 (>78%; present in a 3:1 ratio of M5:M7), with small amounts of cinacalcet and M2a-Glu.
Cinacalcet was extensively metabolized in monkey, with oxidation of the naphthalene ring and N-dealkylation leading to carboxy metabolites as primary metabolic pathways.
This article has not been copyedited and formatted. The final version may differ from this version. In urine, the major metabolites were M2-Glu and M7-Gly. The major metabolite in feces was M1, with significant amounts of unchanged cinacalcet. In bile, the major metabolites were M2-Glu and M1-Glu. The plasma radioactivity was primarily composed of metabolites: M5/M7 (m-CF 3 -hydrocinnamic and m-CF 3 -cinnamic acid, respectively) and dihydrodiol glucuronide M2-Glu. The major metabolites in plasma were M5/M7
(CF 3 -cinnamic and CF 3 -hydrocinnamic acids, respectively, present in an approximately 1:1 ratio) and M2-Glu. Based on the AUC ratio of total plasma radioactivity and unchanged cinacalcet in monkeys, less than 0.5% of the cinacalcet -derived radioactivity in plasma was due to cinacalcet, with M2-Glu (59%) and M5/M7 (32%) as the predominant components (Fig 1) .
Urinary elimination was the predominant route of excretion of cinacalcet-derived radioactivity in humans. The major routes of metabolism were identified as oxidation of the naphthalene ring system leading to dihydrodiols (eliminated as glucuronide conjugates M2a-Glu and M2b-Glu) and N-dealkylation leading to carboxy metabolites (eliminated as glycine conjugates M7-Gly and M8-Gly). At 3 h postdose, the total plasma radioactivity in non-smoking human subjects was 2.85 ± 0.223 µg eq/g, with M5
accounting for 73% of the radioactivity. Minor amounts of dihydrodiol-glucuronides (M2a-Glu and M2b-Glu; 11% of plasma radioactivity), and M6 (hydroxy-3'-CF 3 -hydrocinnamic acid; 9% of plasma radioactivity) were also observed in human plasma.
A similar quantitative profile of metabolites was observed in smokers. Based on the comparison of the AUC values of total radioactivity and unchanged cinacalcet, cinacalcet accounted for <0.5% of the circulating radioactivity in humans.
Discussion
Cinacalcet was well absorbed and extensively metabolized in all species examined, with a broad similarity in the metabolic pathways. The proposed major metabolic pathways of cinacalcet are summarized in Fig 9 and the quantitative analyses are summarized in Table 4 . The primary routes of metabolism of cinacalcet were N-dealkylation leading to carboxylic acid derivatives and oxidation of naphthalene ring system to form dihydrodiols. The oxidative metabolites were conjugated before elimination. The extent of metabolism occurring via N-dealkylation pathway was higher in mice compared to monkeys and humans. The carboxylic acid metabolites (M5/M6/M7) and dihydrodiol glucuronides (M2-Glu) were the predominant components of circulating radioactivity.
The relative circulating levels of M2-Glu were higher in monkey and human than in mouse plasma, possibly due more facile N-dealkylation in mice. Another noticeable difference is the greater extent of radioactive dose excreted via urinary route in humans compared to animal models, 80% versus 35 to 69%. It is not known if the relatively higher urinary excretion of radioactivity in humans is due to the lower dose used for human study (approximately 1 mg/kg) compared to animal studies (10-100 mg/kg).
Compounds containing naphthalene and quinoline ring systems are known to undergo oxidative metabolism to form dihydrodiols (Vickers et al, 1999, Scatz and Haber, 1986; Grossman et al, 1993) . In the case of terbinafine, several positional isomers of dihydrodiol metabolites were reported, with oxidation occurring on either ring of the naphthalene. Similarly, both rings of naphthalene in cinacalcet were subject to oxidation with multiple positional isomers of dihydrodiols. Unlike many other drugs with dihydrodiol metabolites, glucuronide conjugation of dihydrodiol metabolites of cinacalcet appears to be facile. There was no indication for the presence of glutathione conjugates Circulating metabolites can potentially contribute to the therapeutic and/or toxicological effects of a therapeutic. The importance of major circulating metabolites in safety testing and monitoring is dealt in detail in a recent publication (Baillie et al, 2002) . It is generally accepted that there should be a qualitative similarity in the profile of circulating drugrelated material in human and animal models to demonstrate the appropriateness of the preclinical toxicology species. In some instances, circulating metabolites could have longer terminal half-life than parent (Cox et al, 2002) , which could potentially be of consequence when they are either toxic or active. In the case of cinacalcet, the circulating radioactivity was primarily due to metabolites in both animal models as well as humans. However, in an in vitro pharmacology assay, the circulating metabolites of 
